As featured in the 'Manufacturing Chemist' publication, 14th April 2020
WHO has estimated 50% of vaccines are wasted due to refrigeration failure and Stablepharma believe the trehalose-based technique could help with distribution of the COVID-19 vaccine.
The current candidates for a COVID-19 vaccine include re-purposed drugs; established antivirals; monoclonal antibodies; non-specific therapeutics and new vaccines in development such as recombinant live virus vectors.
Currently, the World Health Organisation (WHO) estimates that 50% of the world's vaccines are rendered ineffective due to failings in the delivery and storage refrigeration processes, known as the 'The Cold Chain'. The breakthrough will enable countries to confidently stockpile vaccinations that can be instantly injected, ultimately saving lives.
A British invention could form a crucial role in the urgent quest to combat COVID-19 and future virus pandemics. StablevaX allows vaccines to be transported and stored for years in a syringe without refrigeration. StablevaX has been shown to thermally stabilise examples of all these classes of product, while complying with the vaccination protocols set by the WHO.
"We have investigated the current candidates for a COVID-19 vaccine and believe that our technology would be highly beneficial in the fight against the COVID-19 pandemic. StablevaX provides a solution that eradicates the reliance on the cold chain and enables vaccine stockpiling anywhere in the world. Stablepharma stands ready to make our technologies widely available in the global fight against the Covid-19 pandemic by partnering with vaccine manufacturers to save many lives." said Stablepharma Managing Director and Founder, Nick Child.
Stablepharma uses trehalose to stabilise pre-approved vaccines by drying the correct dose inside a special sponge and housing the sponge in a normal syringe. The result is an instantly injectable life-saving vaccine, at the correct dose, that can be stored on a shelf in just about any climate. Notoriously unstable naked RNA is uniquely rendered stable at c. 45⁰C.
Over 50 pharmaceutical, biotechnology and R&D products stabilised in this way show extreme thermal stability measured in years at high temperatures >45⁰C. Live virus vectors such as Adenovirus and MVA poxvirus can be rendered stable for many months.
The benefit of StablevaX is its ability to enable vaccines to be delivered and even stockpiled in the most inhospitable parts of the world, negating the expensive and unreliable 'cold chain' and thereby allowing vaccines to reach everyone, everywhere.